MicroStrategy files 8-K, sets $0.80 monthly dividend on STRC preferred

[Form 4] BioXcel Therapeutics, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MicroStrategy Incorporated filed a Form 8-K on 31 Jul 2025 to furnish a press release (Exhibit 99.1) containing its financial results for the quarter ended 30 Jun 2025. The actual revenue, earnings and margin figures are not included in the filing and are therefore not deemed 鈥渇iled鈥� under the Exchange Act.

Separately, under Item 8.01, the board declared a $0.80 monthly cash dividend on the Variable Rate Series A Perpetual Stretch Preferred Stock (ticker STRC). The dividend covers the accrual period beginning 29 Jul 2025鈥擲TRC鈥檚 issuance date鈥攁nd will be paid on 31 Aug 2025 to shareholders of record as of 15 Aug 2025.

Positive

$0.80 monthly dividend declared on STRC preferred, confirming cash-flow support for those securities.

Negative

None.

Insights

TL;DR: Dividend declared, but no hard Q2 numbers; minimal impact on common shareholders.

The 8-K is largely procedural. Furnishing鈥攏ot filing鈥攖he Q2 press release shields the company from Section 18 liability, suggesting management wants flexibility before the 10-Q. The $0.80 monthly dividend on STRC implies an annualized rate near 9.6%, consistent with prior guidance and supportive for preferred holders鈥� yield expectations. Because no financial metrics were disclosed in-line, the filing offers little new information about operating performance, leaving equity valuation unchanged. Impact: neutral for common equity, modestly positive for STRC holders.

07/31/2025 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACK DAVID J.

(Last)

(First)

(Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN

06511

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/31/2025		M		1,693	A	⁽¹⁾	15,237	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	07/31/2025		M			1,693	⁽²⁾	⁽²⁾	Common Stock	1,693	$0	5,080	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.

	/s/ Richard Steinhart, Attorney-in-Fact for David J. Mack	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did MicroStrategy (MSTR) announce in its 31 Jul 2025 Form 8-K?

The company furnished its Q2-25 earnings press release and declared a $0.80 monthly dividend on STRC preferred shares.

When is the STRC preferred dividend payable and what is the record date?

Payment is scheduled for 31 Aug 2025 to shareholders of record at the close of business on 15 Aug 2025.

What is the annualized yield of the $0.80 monthly STRC dividend?

The $0.80 monthly payout equates to approximately $9.60 per share annually, or about 9.6% on a $100 par value.

Did the 8-K include detailed Q2-25 financial results for MicroStrategy?

No. The filing references the results in Exhibit 99.1 but does not provide specific revenue or earnings figures.

Are the furnished Q2 results considered "filed" with the SEC?

No. Under Item 2.02, the information is furnished, not filed, and is therefore not subject to Section 18 liabilities.

AG真人官方

[Form 4] BioXcel Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

What did MicroStrategy (MSTR) announce in its 31 Jul 2025 Form 8-K?

When is the STRC preferred dividend payable and what is the record date?

What is the annualized yield of the $0.80 monthly STRC dividend?

Did the 8-K include detailed Q2-25 financial results for MicroStrategy?

Are the furnished Q2 results considered "filed" with the SEC?

NASDAQ:BTAI

BTAI Rankings

BTAI Latest News

BTAI Latest SEC Filings

BTAI Stock Data

AG真人官方

Trending News

[Form 4] BioXcel Therapeutics, Inc. Insider Trading Activity

Insights

Preferred Equity Analyst neutral

FAQ

What did MicroStrategy (MSTR) announce in its 31 Jul 2025 Form 8-K?

When is the STRC preferred dividend payable and what is the record date?

What is the annualized yield of the $0.80 monthly STRC dividend?

Did the 8-K include detailed Q2-25 financial results for MicroStrategy?

Are the furnished Q2 results considered "filed" with the SEC?

NASDAQ:BTAI

BTAI Rankings

BTAI Latest News

BTAI Latest SEC Filings

BTAI Stock Data